EasyBlog

This is some blog description about this site

AntibioTx Enters Collaboration with Dr. Keith Bostian to Establish Medicinal Chemistry Program

COPENHAGEN, AUGUST 19, 2016 – Dr. Keith Bostian is a well-renowned figure within science of medicine and has extensive experience with biotechnology industry entrepreneurship and has had executive operating roles in companies financed by leading venture firms within biotechnology. 

Morten Sommer, CSO of AntibioTx commented: ”I’m looking very much forward to the collaboration with Dr. Keith Bostian and have strong confidence that Keith will further help to accelerate recent progress on our chemistry platform to develop new chemical entities for treatment of unmet medical needs”.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

In vivo Efficacy Studies of ATx201 Compares Favora...
AntibioTx Invited to Publish ATx201 Results at the...

News